Core Viewpoint - VolitionRx Limited has entered into an amended agreement with Lind Global Asset Management to secure $2,000,000 in funding through the issuance of a senior secured convertible promissory note and a common stock purchase warrant, enhancing its financial position for future growth [1][2]. Group 1: Financial Details - The company will issue a senior secured convertible promissory note with a principal amount of $2,400,000 and a common stock purchase warrant to purchase up to 7,000,350 shares at an exercise price of $0.5714 per share [1]. - The 2026 Note will be repaid in eighteen monthly installments of $133,333 starting six months after issuance, with the option for the investor to increase payments up to $1,000,000 for two months [3]. - A commitment fee of $70,000 will be paid to the investor, deducted from the funding received [1]. Group 2: Previous Agreements - The amended agreement updates a previous securities purchase agreement from May 15, 2025, where the company issued a senior secured convertible promissory note of $7,500,000 and a warrant for 13,020,834 shares [2]. - Both the 2025 and 2026 Notes are secured by the assets of the company and its subsidiaries [2]. Group 3: Regulatory Compliance - The company is required to file a registration statement within 30 days of closing to cover the resale of shares issued upon conversion of the 2026 Note or exercise of the 2026 Warrant [4]. Group 4: Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancers and conditions associated with NETosis [6][7]. - The company's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [8].

Core Insights - VolitionRx Limited has developed the Nu.Q® Vet Feline assay, achieving 100% specificity and detecting over 80% of feline lymphomas, marking a significant advancement in veterinary cancer diagnostics [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on early detection of diseases, including cancers, through blood tests [6][7] - The company aims to make cancer screening a routine part of annual wellness checks for pets, having already successfully rolled out a canine cancer test [3][6] Market Opportunity - The introduction of the feline cancer test could potentially double Volition's total addressable market in the companion animal space, as the canine test is already available in over 20 countries [4][5] - There are approximately 73.8 million pet cats in the U.S., with an estimated 1 in 5 cats likely to develop cancer in their lifetime, highlighting a significant market need [5] - The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with the feline segment expected to grow at a faster rate than the canine segment due to increasing owner awareness [5] Product Development and Revenue Potential - The successful publication of the study in a peer-reviewed journal is anticipated to unlock a $5 million contractual milestone payment for Volition [5] - The company is focused on completing product development and making the Nu.Q® Vet Feline Test available through existing distribution networks [3][4]

Core Insights - Oryzon Genomics, a clinical-stage biopharmaceutical company, is a leader in epigenetics and focuses on personalized medicine for CNS disorders and oncology [3] Group 1: Upcoming Events - Oryzon management will participate in the 9th Sachs Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco, with a presentation scheduled at 10:35 am (PST) [1] - The company will also attend the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, and the Allinvest Securities Biomed Forum on January 29, 2026, in Paris, where one-on-one meetings will be available [2] Group 2: Company Overview - Founded in 2000 in Barcelona, Oryzon is recognized as the European leader in epigenetics, with a clinical portfolio that includes two LSD1 inhibitors: vafidemstat (Phase III-ready) for CNS and iadademstat (Phase II) for oncology/hematology [3] - The company is developing other pipeline assets targeting epigenetic mechanisms, including ORY-4001 for potential use in CMT and ALS, and has a robust platform for biomarker identification and target validation across various malignant and neurological diseases [3]

Company Overview - VolitionRx is focused on saving lives and improving outcomes through low-cost testing in cancer, sepsis, and veterinary applications[4, 5] - The company operates with a low capex, low opex business model, emphasizing commercial partnerships and out-licensing[21] - VolitionRx leverages its IP Powerhouse with 56 patent families and a team with hundreds of years of experience[5] Commercialization and Licensing - The company received $10 million upfront and $13 million in milestone payments from an exclusive Element i+ in-house analyzer licensing partnership[29] - In 2024, Volition sold over 120,000 Nu.Q® Vet Cancer Tests & Components[40] - The company is targeting multiple licensing deals in the human space in 2026, focusing on upfront, milestone, and recurring revenue[25] Products and Market - Nu.Q® Vet is available in the United States, Europe, and Asia, detecting 76% of systemic cancers at 97% specificity[38, 40] - The company estimates a $170 million non-regulated animal testing licensing market, a $4 billion lab-developed screening/management market, and a >$3 billion ICU/ED CE Mark/FDA NETosis sales & licensing market[36] - Lung cancer screening and disease management with Nu.Q® is forecasted to reach over 3 million tests by 2035[63]

Core Insights - Oryzon Genomics has received a patent grant from the Japanese Patent Office for its application related to combinations of iadademstat for cancer therapy, which is a significant step in enhancing its patent portfolio [1][2][3] Patent Protection - The granted patent is expected to remain effective until at least 2040, excluding any potential extensions, securing Oryzon's intellectual property in Europe, Japan, Australia, and Russia [2] - Oryzon is actively pursuing corresponding patent applications in other countries to further strengthen its global patent coverage [2] Clinical Development - Iadademstat is being evaluated in combination with immune checkpoint inhibitors, specifically atezolizumab and durvalumab, for the treatment of small cell lung cancer (SCLC) in an ongoing Phase I/II trial sponsored by the U.S. National Cancer Institute [3] - The trial is being conducted at over 30 clinical sites across the U.S., including prestigious institutions like Memorial Sloan Kettering Cancer Center and Johns Hopkins [3] Company Overview - Founded in 2000, Oryzon Genomics is a clinical-stage biopharmaceutical company based in Barcelona, Spain, focusing on epigenetics and personalized medicine in oncology and CNS disorders [4] - The company has a robust clinical portfolio, including two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [4] Iadademstat Details - Iadademstat (ORY-1001) is a selective inhibitor of the epigenetic enzyme LSD1, showing promising results in hematologic cancers and is currently in various clinical trials for conditions such as acute myeloid leukemia (AML) and small cell lung cancer [5][6] - The drug has demonstrated safety and preliminary efficacy in multiple trials, including a Phase IIa trial in combination with azacitidine for elderly AML patients [5]

Core Insights - VolitionRx Limited has made significant progress in 2025, focusing on the commercialization of its Nu.Q® platform for human diagnostics, with key milestones achieved in cancer and sepsis detection [2][3][4] Group 1: Business Developments - The company received its first order for Nu.Q® Cancer assays for clinical certification in lung cancer and included the Nu.Q® NETs assay in a government-backed program in France for early sepsis detection, valued at approximately $7.3 million [3][4] - Volition signed two licensing agreements with major companies, Werfen and Hologic, marking a strategic move into the human diagnostics market [5] - The company is in discussions with around 10 leading diagnostic and liquid biopsy companies to secure additional licensing agreements, anticipating announcements throughout 2026 [6][7] Group 2: Financial Opportunities - The Total Addressable Markets (TAMs) for Volition's technologies are substantial, including $2.3 billion for lung cancer screening, $23 billion for multi-cancer early detection, and $2.8 billion for sepsis early detection [11] - The company aims to replicate its successful licensing strategy in the veterinary market within the human diagnostics space, with potential for diverse deal structures and recurring revenue [7][10] Group 3: Scientific and Clinical Progress - Volition's Nu.Q® NETs assay is being evaluated in over 20 hospitals across 10 countries for various clinical use cases, indicating its potential to become a routine blood test [8] - The company has achieved significant scientific advancements, including the development of a lateral flow test for quantifying nucleosomes, which aids in clinical decision-making [10] - A large-scale study demonstrated that the Nu.Q® NETs H3.1 biomarker is an independent predictor of mortality in sepsis patients, showcasing the assay's clinical relevance [10]

Core Insights - Oryzon Genomics S.A. held an Extraordinary General Shareholders' Meeting where 33,581,589 voting rights were represented, accounting for 37.7938% of the share capital [1][6]. Resolutions Approved - All resolutions proposed by the Board of Directors received favorable votes ranging from 93% to 98% [2]. - Key resolutions included amendments to the Company's Bylaws, approval of a new Remuneration Policy for directors, and a Long-Term Incentive Plan for executives [7]. Financial and Corporate Actions - A capital increase of up to €125 million was approved, with the exclusion of preemptive subscription rights [7]. - The Company is focused on personalized medicine in CNS disorders and oncology/hematology, with a clinical portfolio that includes two LSD1 inhibitors [4].

Core Insights - VolitionRx Limited has announced a new manuscript detailing a novel method, Capture-Seq™, for detecting cancer biomarkers through the analysis of transcription factor protected cfDNA in plasma, which promises accurate and low-cost cancer tests [1][3][4] Technology and Methodology - The new method allows for the physical enrichment of ultrashort DNA fragments bound to transcription factors, achieving a 180-fold enrichment (18,000%) compared to traditional methods that lose the DNA's chromosomal context [2][4] - By isolating ultrashort transcription factor-bound DNA, Volition's technology effectively removes 99% of background DNA, addressing the challenge of interference in liquid biopsy tests for early-stage cancer [4][5] Clinical Results - In a small training cohort of 70 individuals, including 49 cancer patients, the analysis demonstrated 100% sensitivity and specificity in detecting cancer, including early-stage cases [7] Commercial Potential - The company sees significant commercial opportunities with a Total Addressable Market estimated at approximately $23 billion annually, and is actively seeking partnerships to accelerate the technology's integration and launch [9][10] Company Overview - VolitionRx is focused on advancing epigenetics and developing cost-effective blood tests for early disease detection and monitoring, with research and development activities centered in Belgium and additional offices in the U.S. and London [10][11]

Core Insights - VolitionRx Limited's Nu.Q® NETs H3.1 assay has been included in the DETECSEPS program, aimed at early detection of sepsis, which is a significant public health concern [1][3][5] - The DETECSEPS Consortium has received approximately €6.3 million (~$7.3 million) in funding from the French government as part of the France 2030 plan [1][11] - The program seeks to reduce the socio-economic burden of sepsis, which affects around 166 million people globally and resulted in 21.4 million deaths in 2021 [4][11] Company Overview - VolitionRx is a multi-national epigenetics company focused on developing blood tests for early detection and monitoring of diseases, including sepsis [22][23] - The company aims to operationalize its understanding of epigenetics in clinical practice, particularly through the use of the H3.1 biomarker [9] - Volition's collaboration with Euroimmun will utilize the IDS i10® automated analyzer for routine measurement of H3.1 levels, providing results within one hour [8][9] Industry Context - Sepsis presents a heavy social, economic, and health burden, with significant long-term complications for survivors, including high rates of re-admission and mortality [4][10] - The DETECSEPS program is expected to implement an innovative early screening strategy combining clinical scores and the Nu.Q® H3.1 biomarker, which has shown strong diagnostic performance [5][7] - The potential market for sepsis testing is substantial, with the opportunity representing a multi-billion dollar total addressable market [11]

Core Insights - VolitionRx Limited has made its first sale of Nu.Q® Cancer assays to Hospices Civils de Lyon, a leading cancer center in Europe, marking a significant milestone in the commercialization of its cancer diagnostic technology [1][3]. Company Developments - The order from Hospices Civils de Lyon is intended to complete the internal certification process before the test is introduced into routine clinical practice for cancer management [2]. - The collaboration with the Lyon team has resulted in strong scientific and clinical evidence supporting the use of Nu.Q® in managing cancer patients, particularly in Non-Small Cell Lung Cancer [3]. Product Impact - Nu.Q® Cancer technology is designed to enhance clinical decision-making by providing valuable information on survival and progression-free survival, thus improving patient outcomes [3]. - The technology aims to empower clinicians with better monitoring capabilities throughout the patient journey, ultimately supporting patient-centered care [3]. Market Position - This sale represents a major step for Volition in the human cancer diagnostics market, aligning with the company's mission to save lives through earlier detection and improved treatment monitoring [3][4]. - Volition is focused on developing cost-effective blood tests for various diseases, including cancers, which could significantly enhance early detection and patient quality of life [4].